CJC-1295 Research
Long-Acting GHRH Analog
Research area: growth hormone signaling
CJC-1295 is a synthetic analog of GHRH (growth hormone releasing hormone) modified to extend its plasma half-life through albumin binding. It is studied for its role in growth hormone signaling, extended half-life pharmacokinetics, and downstream cellular pathway research.
Research Areas
GHRH Receptor Signaling
Research examines CJC-1295's binding to GHRH receptors on pituitary somatotrophs and its stimulation of GH release, comparing its signaling profile to native GHRH with its extended half-life pharmacokinetics.
IGF-1 & Anabolic Signaling
Phase 1/2 clinical studies investigated sustained elevations in IGF-1 following CJC-1295 administration, with research examining downstream anabolic signaling pathway effects.
Pharmacokinetics Research
The DAC (drug affinity complex) technology in CJC-1295 enables albumin binding that extends half-life to several days. Research investigates this pharmacokinetic modification and its implications for GH axis signaling duration.
GHRH analog research; investigational compound.
Research References
Discuss any health concerns with a licensed clinician before making health decisions.
Have questions about CJC-1295?
Request a free consultation to ask questions and learn more about this research area.
Affiliate disclosure: I am an independent affiliate of The Longevity Consultants and may receive compensation if you request a consultation through me.
Request a free consultation